JP2008506355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008506355A5 JP2008506355A5 JP2007500356A JP2007500356A JP2008506355A5 JP 2008506355 A5 JP2008506355 A5 JP 2008506355A5 JP 2007500356 A JP2007500356 A JP 2007500356A JP 2007500356 A JP2007500356 A JP 2007500356A JP 2008506355 A5 JP2008506355 A5 JP 2008506355A5
- Authority
- JP
- Japan
- Prior art keywords
- biotinylated
- antibody
- fragment
- derivative
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 29
- 230000002797 proteolythic effect Effects 0.000 claims 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 108090001008 Avidin Proteins 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 230000000890 antigenic effect Effects 0.000 claims 5
- 229960002685 biotin Drugs 0.000 claims 5
- 235000020958 biotin Nutrition 0.000 claims 5
- 239000011616 biotin Substances 0.000 claims 5
- 101000666340 Homo sapiens Tenascin Proteins 0.000 claims 4
- 102000007000 Tenascin Human genes 0.000 claims 4
- 108010008125 Tenascin Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000011363 radioimmunotherapy Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940088623 biologically active substance Drugs 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000105A ITRM20040105A1 (it) | 2004-02-27 | 2004-02-27 | Anticorpo monoclonale antitenascina umana. |
| ITRM2004A000105 | 2004-02-27 | ||
| PCT/IT2005/000078 WO2005082938A2 (en) | 2004-02-27 | 2005-02-16 | Anti-human tenascin monoclonal antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008506355A JP2008506355A (ja) | 2008-03-06 |
| JP2008506355A5 true JP2008506355A5 (enExample) | 2008-04-17 |
| JP5191036B2 JP5191036B2 (ja) | 2013-04-24 |
Family
ID=34897820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500356A Expired - Fee Related JP5191036B2 (ja) | 2004-02-27 | 2005-02-16 | 抗ヒトテネイシンモノクローナル抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7989171B2 (enExample) |
| EP (1) | EP1718678B1 (enExample) |
| JP (1) | JP5191036B2 (enExample) |
| KR (1) | KR101266389B1 (enExample) |
| CN (1) | CN1946740B (enExample) |
| AR (1) | AR047819A1 (enExample) |
| AU (1) | AU2005217237B2 (enExample) |
| BR (1) | BRPI0508082A8 (enExample) |
| CA (1) | CA2558718C (enExample) |
| ES (1) | ES2654065T3 (enExample) |
| IT (1) | ITRM20040105A1 (enExample) |
| MX (1) | MXPA06009674A (enExample) |
| PL (1) | PL1718678T3 (enExample) |
| PT (1) | PT1718678T (enExample) |
| WO (1) | WO2005082938A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006086769A2 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| JP2012031084A (ja) * | 2010-07-29 | 2012-02-16 | Tokyo Univ Of Science | 抗腫瘍剤 |
| WO2014113459A1 (en) * | 2013-01-15 | 2014-07-24 | Duke University | Hiv-1 neutralizing factor |
| EP2999967B1 (en) | 2013-05-21 | 2020-05-20 | NX Pharmagen | Use of tenascin-c as an extracellular marker of tumor-derived microparticles |
| GB201414021D0 (en) * | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| GB201616596D0 (en) * | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| CN119019548B (zh) * | 2022-07-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5634076A (en) * | 1994-10-04 | 1997-05-27 | Analog Devices, Inc. | DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer |
| US6014709A (en) * | 1997-11-05 | 2000-01-11 | Unisys Corporation | Message flow protocol for avoiding deadlocks |
| US6335014B1 (en) * | 1998-06-17 | 2002-01-01 | The Institute Of Physical And Chemical Research | Medicament for suppressing cancer metastasis |
| US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| AU4682100A (en) * | 1999-05-01 | 2000-11-17 | University Of Medicine And Dentistry Of New Jersey | Neurite outgrowth and guidance by tenascin-c |
| US7058750B1 (en) * | 2000-05-10 | 2006-06-06 | Intel Corporation | Scalable distributed memory and I/O multiprocessor system |
| JP3646159B2 (ja) * | 2001-02-08 | 2005-05-11 | 国立大学法人三重大学 | 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ |
| ITRM20010079A1 (it) * | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| SI1478667T1 (sl) * | 2002-02-26 | 2010-12-31 | Sigma Tau Ind Farmaceuti | Monoklonski protitelesni anti-äśloveĺ ki tenascin |
| ITRM20020128A1 (it) * | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
-
2004
- 2004-02-27 IT IT000105A patent/ITRM20040105A1/it unknown
-
2005
- 2005-02-16 MX MXPA06009674A patent/MXPA06009674A/es active IP Right Grant
- 2005-02-16 PT PT57189888T patent/PT1718678T/pt unknown
- 2005-02-16 BR BRPI0508082A patent/BRPI0508082A8/pt not_active IP Right Cessation
- 2005-02-16 CN CN2005800061324A patent/CN1946740B/zh not_active Expired - Fee Related
- 2005-02-16 US US10/590,936 patent/US7989171B2/en not_active Expired - Fee Related
- 2005-02-16 AU AU2005217237A patent/AU2005217237B2/en not_active Ceased
- 2005-02-16 EP EP05718988.8A patent/EP1718678B1/en not_active Expired - Lifetime
- 2005-02-16 CA CA2558718A patent/CA2558718C/en not_active Expired - Fee Related
- 2005-02-16 PL PL05718988T patent/PL1718678T3/pl unknown
- 2005-02-16 WO PCT/IT2005/000078 patent/WO2005082938A2/en not_active Ceased
- 2005-02-16 JP JP2007500356A patent/JP5191036B2/ja not_active Expired - Fee Related
- 2005-02-16 ES ES05718988.8T patent/ES2654065T3/es not_active Expired - Lifetime
- 2005-02-24 AR ARP050100671A patent/AR047819A1/es not_active Application Discontinuation
-
2006
- 2006-09-27 KR KR1020067020062A patent/KR101266389B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5084267B2 (ja) | 多特異性抗体との使用のための治療および診断用コンジュゲート | |
| CN100560131C (zh) | 抗体靶向化合物 | |
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| KR101085784B1 (ko) | 인테그린 표적화 화합물 | |
| US20200392108A1 (en) | Antibody-drug conjugates and related compounds, compositions and methods | |
| JP2005534615A5 (enExample) | ||
| BR112020014380A2 (pt) | Anticorpo anti-mesotelina e conjugado de fármaco anticorpo do mesmo | |
| US9701754B1 (en) | Covalent disulfide-linked diabodies and uses thereof | |
| AU2002337954A1 (en) | Integrin targeting compounds | |
| CN112601522A (zh) | 抗体-alk5抑制剂偶联物及其用途 | |
| RU2007116973A (ru) | Терапевтические средства с пониженной токсичностью | |
| JP2008506355A5 (enExample) | ||
| Mayer et al. | Taking engineered anti-CEA antibodies to the clinic | |
| JP5191036B2 (ja) | 抗ヒトテネイシンモノクローナル抗体 | |
| CN114269388A (zh) | 抗体-alk5抑制剂缀合物及其用途 | |
| JPWO2023083846A5 (enExample) | ||
| CN112739386B (zh) | 用于dota-预靶向放射免疫疗法的n-乙酰半乳糖氨基树枝状物清除剂 | |
| WO2024235135A1 (zh) | 大环化合物及其制备方法和用途 | |
| WO2024235123A1 (zh) | 具有抗肿瘤作用的化合物及其制备方法和用途 | |
| CN119894536A (zh) | Gpc3抗体药物偶联物及其应用 | |
| TW202515913A (zh) | Nectin-4抗體及抗體藥物結合物 | |
| HK1100848B (en) | Anti-human tenascin monoclonal antibody |